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Abstract

NIH-PA Author Manuscript

The rise of antibiotic resistant pathogens focuses our attention on the source of antibiotic
resistance genes, on the existence of these genes in environments exposed to little or no
antibiotics, and on the relationship between resistance genes found in the clinic and those
encountered in non-clinical settings. Here, we address the evolutionary history of a class of
resistance genes, the SHV β-lactamases. We focus on blaSHV genes isolated both from clinical and
non-clinical sources and show that clinically important resistance determinants arise repeatedly
from within a diverse pool of blaSHV genes present in the environment. While our results argue
against the notion of a single common origin for all clinically-derived blaSHV genes, we detect a
characteristic selective signature shaping this protein in clinical environments. This clinical
signature reveals the joint action of purifying and positive selection on specific residues, including
those known to confer extended-spectrum activity. Surprisingly, antibiotic resistance genes
isolated from non-clinical -- and presumably antibiotic-free -- settings also experience the joint
action of purifying and positive selection. The picture that emerges undercuts the notion of a
separate reservoir of antibiotic resistance genes confined only to clinical settings. Instead, we
argue for the presence of a single extensive and variable pool of antibiotic resistance genes present
in the environment.
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Introduction
Clinically relevant antibiotic resistance, first noted soon after the introduction of penicillin
for the treatment of wound-related infections in WWII, has increased dramatically over the
past 70 years. In that time, our knowledge of the diversity and abundance of resistance
mechanisms has expanded considerably, and their presence has led to the current situation:
increasing morbidity and mortality due to bacterial infections, increased cost and duration of
hospital stays, and a rise in the number of infections that respond to few, if any, existing
antibiotics (Bush et al. 2011).
The causes underlying this increase in resistant bacterial pathogens have been extensively
scrutinized. They range from the overuse of antibiotics in clinical and agricultural settings to
the extensive traffic in resistance determinants (both within and across species boundaries)
#
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mediated by a variety of mobile genetic elements (Blaser 2011; Bush et al. 2011; Stokes and
Gillings 2011). In response to the rapid spread of these resistance determinants, surveillance
networks monitoring the dynamics and spread of resistance are now in place (Grundmann et
al. 2011). While these efforts have revealed the speed with which a single resistant clonal
lineage or resistance mechanism can spread around the world, the origins of resistance
mechanisms remain comparatively unaddressed.
We are particularly interested in understanding the source of the diversity of resistance
determinants seen in clinical isolates of pathogenic bacteria. Numerous studies have
suggested that these genes arise in a clinical setting in response to human-mediated
antibiotic usage (Costelloe et al. 2010; Medeiros 1997; Wright 2010). More recent studies
reveal that the environment can also serve as a reservoir for resistance determinants (Allen
et al. 2010; Davies and Davies 2010). Here, we explore the relationship between
environmentally- and clinically-derived resistance determinants by examining their
molecular evolutionary history.
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Our analysis focuses on a specific class of antibiotic resistance genes, the blaSHV genes,
which encode β-lactamases. Based on conserved and distinctive amino acid motifs, SHV is
considered a Class A group 2b enzyme (Bush and Jacoby 2010). This enzyme, encoded by a
gene that is often located on a plasmid, is of particular interest because of its wide
phylogenetic distribution within the Enterobacteriaceae and its presence in a range of
clinically relevant pathogens, including Acinetobacter baumannii, Salmonella enterica,
Shigella dysenteriae, Yersinia pestis, and Pseudomonas aeruginosa. Functionally, SHV is
one of the three major extended spectrum β-lactamase (ESBL)-producers (Drawz and
Bonomo 2010). Our attention was thus directed to this class of resistance genes because of
their widespread distribution, clinical importance, and the availability of a significant
number of sequences in the National Center for Biotechnology Information (NCBI)
database.
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An understanding of the evolutionary history of blaSHV depends on a dataset that fully
captures its sequence diversity. While studies exist that identify this gene in the
environment, none provide sequence data for those isolates (Chikwendu et al. 2011; Costa et
al. 2006; Girlich et al. 2011; Literak et al. 2010). We address this deficiency here by
reporting a set of 28 blaSHV sequences (15 of which are non-redundant) identified by
screening 109 strains isolated from fecal samples of Australian placental and marsupial
mammals, collected between 1993 and 1997 in environments far from human habitation
(Gordon and FitzGibbon 1999). We also report a contemporaneous set of 40 clinicallyderived sequences (24 of which are non-redundant) of isolates collected from hospitals in
Sydney, Australia (Gordon et al. 2005). We complete the dataset by including a sample of
71 sequences that reflect the diversity of non-redundant, full-length blaSHV clinical
sequences present in the NCBI database (Online Resource 1). We note that no blaSHV
environmental sequences were present in the NCBI database.

Materials and Methods
Bacterial Strains
The bacterial strains in this study were obtained from the Australian Enteric Collection of
Dr. David Gordon (Australian National University) (Gordon and FitzGibbon 1999), and
were isolated between 1993–1997 either from fecal samples of mammals in the Australian
outback (regions with little to no human-association) or from hospital patients in Sydney,
Australia and screened for the blaSHV gene. Sequences for hospital-derived blaSHV genes
(n=40) were kindly provided by Dr. David Gordon.
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Genotypic Characterization
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DNA was isolated from bacterial strains with the DNeasy® Tissue Kit (Qiagen, Valencia,
CA, USA). Strains were PCR-screened using a standard protocol with primers specific for
the blaSHV gene (Online Resource 2). PCR products were purified using the QIAquick®
PCR Purification Kit (Qiagen, Valencia, CA, USA) and sequenced with Big Dye®
Sequencing Mix V3.1 (Applied Biosystems, Foster City, CA, USA) under standard
conditions and run on an ABI 3100 Genetic Analyzer.
Database Sequences

blaSHV sequences were retrieved from NCBI using a non-redundant protein BLAST search
queried with Misc025. All sequences with an identity ≥ 97% and an E-value ≤ 10−180 were
retrieved; partial sequences were excluded. The origin of every sequence (clinical or
environmental) was ascertained using NCBI annotations. Sequences of unknown origin were
excluded. Only one identical sequence per origin was gathered, yielding a total of 71
sequences. Duplicate sequences were only retained when they were derived from different
environments (See Online Resource 1 for strains included in data analysis). Sequences were
aligned using ClustalW2.
Phylogenetic Reconstruction

NIH-PA Author Manuscript

A Bayesian tree for the blaSHV nucleotide sequences was constructed using MrBayes
(Ronquist and Huelsenbeck 2003), (GTR model, across-site rate variation = Invgamma,
outgroup accession number AY743416.1). 3×106 generations were run with a sampling of
trees every 1000 generations, resulting in convergence and a 0.027 average standard
deviation of split frequencies. The “Sump burnin” and “Sumt burnin” options in MrBayes
result in the discarding of the first 25% of generated samples. Posterior probabilities are
reported for any clade falling below 80%.
Selection Analysis
Nonsynonymous (dN) and synonymous (dS) substitution rates were estimated using the
Selecton Server (Stern et al. 2007). Clinical and environmental sequences were treated as
separate samples. Branch length optimization was selected and all analyses were run using
both model 8 (positive selection), and model 8a (null model). Selected sites were mapped
onto the crystal structure of the SHV-1 β-lactamase (PDB 1SHV) (Kuzin et al. 1999).
Likelihood values are reported in Online Resource 3.

Results and Discussion
NIH-PA Author Manuscript

The sequences we examine in this study shed light on the extraordinary diversity of SHV
resistance determinants. More than 500 blaSHV sequences, encoding over 150 unique protein
sequences, have been deposited in NCBI (2012). Of the Australian environmentally-derived
blaSHV sequences reported here (n=28), 9 nucleotide and 2 protein sequences were novel to
NCBI. In the Australian clinically-derived sequences (n=24), 12 nucleotide and 2 protein
sequences were also new to NCBI. The Australian environmental and clinical sets share
only one previously undescribed SHV protein sequence.
We subjected these blaSHV sequences (n=110) to two distinct analyses. In the first of these,
sequences were aligned and used to generate Bayesian rooted phylogenetic trees based on
their nucleotide sequences (Ronquist and Huelsenbeck 2003). The prevailing view
concerning the evolution of resistance genes argues that human-mediated selection is the
primary driver (Costelloe et al. 2010; Medeiros 1997; Wright 2010), leading to the
phylogenetic prediction depicted in Figure 1a, where all clinically-derived SHV sequences
form a distinct subclade on the blaSHV phylogeny. Our results contradict that prediction, and
J Mol Evol. Author manuscript; available in PMC 2014 July 17.
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instead yield the consensus tree shown in Figure 1b: a tree with many unresolved nodes, and
multiple mixed subclades composed of both Australian environmental and NCBI/Australian
clinical sequences. Environmental sequences are distributed throughout the tree; while some
subclades are composed exclusively of clinical isolates, this likely reflects the oversampling
of clinical isolates and their overrepresentation in the database. Despite the uncertainty
surrounding the tree topology, the environmental and clinical blaSHV sequences do not give
rise to two distinct subclusters.
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We further explore the relationship between clinical and environmental sequences by
examining the footprint of selection on both datasets. The sequences were subjected to a
Bayesian codon-based selection analysis, using estimates of synonymous (dS) and
nonsynonymous (dN) substitution rates to detect both the presence and character (positive or
purifying) of selection. The results of this analysis are shown in Figures 2a–c. Panel (a)
shows the dN/dS ratio across the entire protein for both the NCBI/Australian clinical and
environmental SHV datasets. Panels (b) (NCBI/Australian clinical sequences) and (c)
(Australian environmental sequences) show selection results mapped directly onto the
resolved crystal structure of the SHV protein (PDB 1SHV) (Kuzin et al. 1999). Space-filled
sites highlight amino acid positions at which positive selection is detected. Sites under
strong purifying selection are shown in grey. The extent of purifying and positive selection
detected suggests that blaSHV genes are not evolving neutrally. We are led to conclude that
the encoded proteins play a significant role in the fitness of their bearers, both in settings
characterized by high antibiotic use and in environments essentially devoid of human
antibiotic use.
In the NCBI/Australian clinical dataset, positive selection is detected at positions 3, 31, 142,
234 and 235. Two of these sites (positions 234 and 235) occur around the active site and
have been associated with ESBL activity (Bradford 2001). Substitutions at site 234 have
also been implicated in the binding of larger β–lactam antibiotics, such as cephems with
bulky side chains (Lee et al. 1991; Nukaga et al. 2003). In addition, positive selection is
detected at site 142 where a study reports a direct link to carbapenemase activity, though
reasons for this are not clear (Mendonca et al. 2008; Poirel et al. 2003).
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Surprisingly, the Australian environmental dataset revealed a higher proportion of residues
under positive selection when compared to their NCBI/Australian clinical counterparts (10
and 5 residues, respectively) (Online Resource 4). For the environmental dataset, positive
selection is detected at positions 3, 14, 31, 65, 125, 137, 140, 152, 191, 272. Only one site of
positive selection (position 65) is detected adjacent to the active-site serine; mutations at this
site have been shown to confer resistance to inhibitors such as clavulanic acid (Randegger
and Hächler 2001). This observation suggests that positive selection near the active site,
generally associated with clinical levels of antibiotic exposure, is not limited to the clinic.
Other sites where positive selection is detected are distributed throughout the protein and do
not cluster in any particular structural subdomain.
In contrast with the similarity of the sites undergoing purifying selection seen in both
samples, there are only two sites (3 and 31) undergoing positive selection shared by the
clinical and environmental datasets. Position 3 is not involved in the enzymatic activity of
the protein as it is cleaved in the formation of the mature protein (Rice et al. 2000). Position
31 exhibits the highest dN/dS ratio for both clinical and environmental datasets, but its
functional significance remains unclear: although it has been suggested that mutations at this
site lead to a conformational change in the protein (Nüesch-Inderbinen et al. 1995). Despite
some overlap, the marked differences between environmental and clinical SHV samples in
the sites undergoing positive selection suggest that our environmental samples are not

J Mol Evol. Author manuscript; available in PMC 2014 July 17.

Dorit et al.

Page 5

simply SHV alleles shaped in the clinic that have recently made their way into the broader
environment.
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Our selection analysis reveals that, in both the environmental and clinical samples, multiple
sites distributed around the protein are undergoing selective scrutiny. Coupled with the clear
phylogenetic signal we describe, the picture that emerges undercuts the notion of a separate
reservoir of antibiotic resistance genes confined only to clinical settings. Instead, we argue
for the presence of a single extensive and variable pool of antibiotic resistance genes present
in the environment. The blaSHV genes seen in clinical settings thus represent a recurrent
sampling of this pool of resistance determinants. This scenario argues for the importance of
extensive and systematic sampling of antibiotic resistance determinants in non-clinical
settings. Clinically relevant pathogens appear to have a vast and as yet largely
uncharacterized cornucopia of resistance determinants at their disposal. A more
comprehensive exploration of the environmental reservoir is likely to shed light on the
emergence and evolution of genes conferring resistance to antibiotics.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Bayesian polar trees of blaSHV clinical and environmental sequences

(a) Hypothetical tree displaying a clear separation of clinically- and environmentallyderived sequences. (b) Actual consensus tree of clinically- and environmentally-derived
blaSHV sequences. There is no clear, definable structure to the tree (largely unresolved) as
well as no segregation between those sequences derived from clinical isolates and those
derived from environmental isolates. Taxon labels: Black: Australian environmental
sequences; Light Grey: Australian clinical sequences; Dark Grey: NCBI clinical sequences.
Posterior probabilities for nodes that were less than 80% are noted with ●
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Fig. 2. Selection analysis results for SHV β-lactamase

(a) dN/dS ratios at each amino acid position for environmental and clinical datasets. A ratio
>1 (dashed line) indicates positive selection. (b) Clinical selection results mapped onto
SHV-1 structure (P < .001). (c) Environmental selection results mapped onto SHV-1
structure (P =.010). Backbone colors ranging from light to dark indicate sites of purifying
selection (strength of selection increasing with color saturation). Space-filled sites show
where positive selection has been detected. Site 31 is the only site where positive selection
has been verified by confidence intervals. Positions are numbered based on our alignments,
their correspondence to the Ambler numbering system is specified in Online Resource 4
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